A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants

NCT04172987 · Completed

Last updated 2026-05-28

This clinical trial is testing how tirzepatide, a medication, may affect the way the body processes birth control pills in healthy women.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 40 people

Who can join Ages 18–45 · female only Healthy volunteers accepted.

Timeline Started 2020-02 · est. completion 2021-02

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT04172987 ↗

Description as written by the study sponsor.

The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side effects that may occur will also be collected. Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 20 weeks, including screening.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
EE/NGM Drug

Combination oral contraceptive administered orally

Main thing measured	Period 1 and Period 2, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Ethinylestradiol (EE)
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04172987 ↗